This report contains a summary of the analyst consensus forecasts available in the the publisher Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 43 drugs indicated for COVID-19 which have analyst consensus forecasts available.
This report gives important, expert insight you won’t find in any other source. 13 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
Scope
This report gives important, expert insight you won’t find in any other source. 13 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
- Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the COVID-19 disease space
- Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space
Reasons to Buy
- Analysis of COVID-19 analyst consensus sales forecasts
- Overview of Pipeline portfolio of companies involved in COVID-19 disease space
- Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs
Table of Contents
1 COVID-19 Global Analyst Consensus Sales Forecast1.1 COVID-19 Prophylactic Vaccines with Global Analyst Consensus Sales Forecast
1.2 COVID-19 Therapeutic Drugs with Global Analyst Consensus Sales Forecast
1.3 COVID-19 Global Analyst Consensus Sales Forecast
1.4 Top Three Marketed COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecast
2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts
2.1 COVID-19 Prophylactic Vaccines Global Analyst Consensus Sales Forecast
2.2 COVID-19 Therapeutic Drugs Global Analyst Consensus Sales Forecast
3 BioNTech SE
3.1 Global Analyst Consensus Sales Forecast – Comirnaty
3.2 Percentage Change from Q3 2021 to Q4 2021 Global Analyst Consensus Sales Forecast – Comirnaty
4 Pfizer
4.1 Global Analyst Consensus Sales Forecast – Paxlovid
5 Merck & Co. Inc.
5.1 Global Analyst Consensus Sales Forecast – Molnupiravir
5.2 Percentage Change from Q3 2021 to Q4 2021 Global Analyst Consensus Sales Forecast – Molnupiravir
6 Johnson & Johnson
6.1 Global Analyst Consensus Sales Forecast – COVID-19 Vaccine
6.2 Percentage Change from Q3 2021 to Q4 2021 Global Analyst Consensus Sales Forecast – COVID-19 Vaccine
7 Key Findings
8 Appendix
8.1 Abbreviations
8.2 Methodology
8.3 Related Reports
8.4 About the Authors
8.5 About The Publisher
8.6 Contact Us
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aclaris Therapeutics Inc
- Arcturus Therapeutics Holdings Inc
- AstraZeneca Plc
- JCR Pharmaceuticals Co Ltd
- Atea Pharmaceuticals Inc
- Atossa Therapeutics Inc
- Eli Lily
- Bavarian Nordic A/S
- BioNTech SE
- CanSino Biologics Inc
- Capricor Therapeutics Inc
- Celltrion Inc
- Cerecor Inc
- Dynavax Technologies Corp
- Eiger BioPharmaceuticals Inc
- F. Hoffmann-La Roche Ltd/Regeneron Pharmaceuticals Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Heat Biologics Inc
- Humanigen Inc
- I-Mab
